Wells Fargo & Company MN Has $476,000 Holdings in Mesa Laboratories, Inc. (MLAB)
Wells Fargo & Company MN lifted its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 19.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,326 shares of the medical instruments supplier’s stock after acquiring an additional 553 shares during the period. Wells Fargo & Company MN owned 0.09% of Mesa Laboratories worth $476,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of MLAB. Strs Ohio lifted its stake in shares of Mesa Laboratories by 5.6% in the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after acquiring an additional 100 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Mesa Laboratories in the 2nd quarter worth approximately $300,000. Bessemer Group Inc. lifted its stake in shares of Mesa Laboratories by 716.7% in the 2nd quarter. Bessemer Group Inc. now owns 4,900 shares of the medical instruments supplier’s stock worth $702,000 after acquiring an additional 4,300 shares during the period. Eqis Capital Management Inc. lifted its stake in shares of Mesa Laboratories by 5.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 5,188 shares of the medical instruments supplier’s stock worth $744,000 after acquiring an additional 273 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Mesa Laboratories by 9.6% in the 2nd quarter. Swiss National Bank now owns 5,702 shares of the medical instruments supplier’s stock worth $817,000 after acquiring an additional 500 shares during the period. 68.83% of the stock is owned by institutional investors.
In related news, Director H Stuart Campbell sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $130.16, for a total value of $130,160.00. Following the sale, the director now directly owns 42,366 shares in the company, valued at approximately $5,514,358.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,002 shares of company stock worth $391,268 over the last quarter. Insiders own 15.70% of the company’s stock.
Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) opened at $126.88 on Monday. The firm has a market cap of $479.58, a P/E ratio of 33.57 and a beta of 0.49. Mesa Laboratories, Inc. has a one year low of $109.14 and a one year high of $169.80. The company has a quick ratio of 1.97, a current ratio of 2.86 and a debt-to-equity ratio of 0.48.
Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.04). Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. The business had revenue of $22.95 million during the quarter, compared to the consensus estimate of $25.50 million. research analysts anticipate that Mesa Laboratories, Inc. will post 2.47 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be issued a $0.16 dividend. The ex-dividend date is Wednesday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.50%. Mesa Laboratories’s payout ratio is currently 23.10%.
A number of analysts have recently weighed in on MLAB shares. Zacks Investment Research raised shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 price target for the company in a research note on Tuesday, October 3rd. BidaskClub lowered shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. Finally, TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/wells-fargo-company-mn-has-476000-holdings-in-mesa-laboratories-inc-mlab/1699317.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.